Anticancer property of Hemp Bioactive Peptides in Hep3B liver cancer cells through Akt/GSK3β/β‐catenin signaling pathway

Foodborne protein hydrolysates exhibit biological activity that may be therapeutic in a number of human disease settings. Hemp peptides (HP) generated by controlled hydrolysis of hemp proteins have a number of health benefits and are of pharmaceutical value. In the present study, we produce small mo...

Full description

Saved in:
Bibliographic Details
Published inFood science & nutrition Vol. 9; no. 4; pp. 1833 - 1841
Main Authors Wei, Lian‐Hui, Dong, Yan, Sun, Yu‐Feng, Mei, Xue‐Song, Ma, Xue‐Song, Shi, Jie, Yang, Qing‐li, Ji, Yan‐Ru, Zhang, Zheng‐Hai, Sun, Hu‐Nan, Sun, Xing‐Rong, Song, Shu‐Min
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.04.2021
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Foodborne protein hydrolysates exhibit biological activity that may be therapeutic in a number of human disease settings. Hemp peptides (HP) generated by controlled hydrolysis of hemp proteins have a number of health benefits and are of pharmaceutical value. In the present study, we produce small molecular weight HP from hemp seed and investigate its anticancer properties in Hep3B human liver cancer cells. We demonstrate that HP treatment increased apoptosis, reduced cell viability, and reduced cell migration in Hep3B human liver cancer cells without affecting the normal liver cell line L02. We correlate these phenotypes with increased cellular ROS levels, upregulation of cleaved caspase 3 and Bad, and downregulation of antiapoptotic Bcl‐2. HP treatment led to increased Akt and GSK‐3β phosphorylation, with subsequent downregulation of β‐catenin, suggesting β‐catenin signaling modulation as a critical mechanism by which HP exhibits anticancer properties. Our findings suggest HP are of potential therapeutic interest for liver cancer treatment. Anti‐cancer property of new hemp protein hydrolysates on human liver cancers
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2048-7177
2048-7177
DOI:10.1002/fsn3.1976